Group 1 - The company reported a revenue of 2.678 billion yuan in 2024, a year-on-year decrease of 1.46%, and a net profit attributable to shareholders of -102 million yuan, a decline of 138.02% [1] - In Q1 2025, the company achieved a revenue of 742 million yuan, a year-on-year increase of 9.82%, and a net profit attributable to shareholders of 27 million yuan, a growth of 61.18% [1] - The company expects a recovery in 2025, driven by improved consumer environment and policy support [2] Group 2 - In 2024, the company's revenue from refractive projects was 1.227 billion yuan, down 5.31% year-on-year, while cataract project revenue was 576 million yuan, down 3.04% [2] - The gross margin for refractive projects in 2024 was 47.02%, a decrease of 4.56 percentage points compared to the same period in 2023 [2] - The overall gross margin in 2024 was 36.98%, down 7.02 percentage points year-on-year, with a net margin of -3.47%, a decline of 13.7 percentage points [3] Group 3 - The company anticipates net profits of 118 million yuan, 197 million yuan, and 255 million yuan for the years 2025, 2026, and 2027 respectively, reflecting adjustments due to factors like artificial crystal procurement and DRG policy [4] - The company is positioned as a leading private ophthalmology medical enterprise in China, with clear expansion plans in provincial capitals [4] - The aging population is expected to drive demand for medical services, supporting the company's growth trajectory [4]